Atypical IgM on T cells predict relapse and steroid dependence in idiopathic nephrotic syndrome

Kidney Int. 2019 Oct;96(4):971-982. doi: 10.1016/j.kint.2019.04.006. Epub 2019 May 7.

Abstract

The clinical heterogeneity of idiopathic nephrotic syndrome in childhood may reflect different mechanisms of disease that are as yet unclear. Here, we evaluated the association between an atypical presence of IgM on the surface of T cells (T-cell IgM) and the response to steroid therapy in a total of 153 pediatric patients with idiopathic nephrotic syndrome in different phases of disease. At disease onset, T-cell IgM median levels were significantly elevated and predictive of risk of relapse in 47 patients. They were also significantly increased comparing 58 steroid-dependent to 8 infrequently relapsing and 14 frequently relapsing patients, especially during relapse, whereas they were within the normal range in 7 genetic steroid-resistant patients. T-cell IgM in vivo was not affected by the amount of total circulating IgM, nor by concomitant acute infections or oral immunosuppression. However, it was affected by rituximab treatment in 21 steroid-dependent patients. By in vitro experiments, elevated T-cell IgM was not influenced by total circulating IgM levels or by the presence of other circulating factors, and there was no distinctive antigen-specificity or atypical IgM polymerization. Rather, we found that increased T-cell IgM correlates with reduced IgM sialylation, which influences T-cell response to steroid inhibition and T-cell production of podocyte-damaging factors. Thus, the atypical presence of IgM on the surface of T cells may predispose a subset of steroid-sensitive pediatric patients with idiopathic nephrotic syndrome to a poor response to steroid therapy since disease onset.

Keywords: lymphocytes; nephrotic syndrome; pediatric nephrology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Drug Resistance / genetics
  • Drug Therapy, Combination / methods
  • Female
  • Follow-Up Studies
  • Glucocorticoids / pharmacology*
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunoglobulin M / analysis
  • Immunoglobulin M / immunology
  • Immunoglobulin M / metabolism*
  • Infant
  • Male
  • Nephrotic Syndrome / blood
  • Nephrotic Syndrome / drug therapy*
  • Nephrotic Syndrome / genetics
  • Nephrotic Syndrome / immunology
  • Podocytes
  • Prospective Studies
  • Recurrence
  • Rituximab / pharmacology
  • Rituximab / therapeutic use
  • Sialic Acids / metabolism
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / metabolism
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Immunoglobulin M
  • Sialic Acids
  • Rituximab